Botulinum Toxin Therapy for Voiding Dysfunction and the Female Pelvic Floor

  • Michael IngberEmail author


Onabotulinum toxin A is an agent which prevents the release of the neurotransmitter acetylcholine at the synaptic cleft. These properties are utilized during injection in order to prevent muscle contraction by cleaving the SNARE protein SNAP-25, preventing docking and fusion of vesicles at the neurovascular terminal. After injection, a long-lasting effect can occur which typically lasts several months. Onabotulinum toxin A has been studied extensively in randomized placebo-controlled clinical trials and has been shown to be an effective agent in the treatment of refractory idiopathic overactive bladder and neurogenic detrusor overactivity. Herein we discuss the history of the development of the neurotoxin, and describe the mechanism of action. We describe the use of onabotulinum toxin A in female urology applications, its risks and complications, and review the available literature. Success in treating these conditions will pave the way for other future applications in urology.


Spinal Cord Injury Interstitial Cystitis Intermittent Catheterization Clean Intermittent Catheterization Neurogenic Detrusor Overactivity 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Erbguth FJ, Naumann M. Historical aspects of botulinum toxin: Justinus Kerner (1786-1862) and the “sausage poison”. Neurology. 1999;53(8):1850–3.PubMedCrossRefGoogle Scholar
  2. 2.
    Dolly O. Synaptic transmission: inhibition of neurotransmitter release by botulinum toxins. Headache. 2003;43 Suppl 1:S16–24.PubMedCrossRefGoogle Scholar
  3. 3.
    Brin MF. Botulinum toxin: chemistry, pharmacology, toxicity, and immunology. Muscle Nerve. 1997;6(Suppl):S146–68.PubMedCrossRefGoogle Scholar
  4. 4.
    Kruht J, Zvara P. Intravesical instillation of botulinum toxin A: an in vivo murine study and pilot clinical trial. Int Urol Nephrol. 2011;43(2):337–43.CrossRefGoogle Scholar
  5. 5.
    Chapple CR. Muscarinic receptor antagonists in the treatment of overactive bladder. Urology. 2000;55:33.PubMedCrossRefGoogle Scholar
  6. 6.
    Wagg A, Compion G, Fahey A, Siddiqui E. Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience. BJU Int. 2012;110(11):1767–74.PubMedCrossRefGoogle Scholar
  7. 7.
    D'Souza AO, Smith MJ, Miller LA, Doyle J, Ariely R. Persistence, adherence, and switch rates among extended-release and immediate-release overactive bladder medications in a regional managed care plan. J Manag Care Pharm. 2008;14(3):291–301.PubMedGoogle Scholar
  8. 8.
    Hollingworth W, Campbell JD, Kowalski J, et al. Exploring the impact of changes in neurogenic urinary incontinence frequency and condition specific quality of life on preference-based outcomes. Qual Life Res. 2010;19:323.PubMedCrossRefGoogle Scholar
  9. 9.
    Schurch B, Stohrer M. Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. J Urol. 2000;164(3 Pt 1):692–7.PubMedCrossRefGoogle Scholar
  10. 10.
    Ginsberg D, Gousse A, Keppenne V, Sievert KD, Thompson C, Lam W, Brin MF, Jenkins B, Haag-Molkenteller C. Phase 3 efficacy and tolerability study of onabotulinumtoxinA for urinary incontinence from neurogenic detrusor overactivity. J Urol. 2012;187(6):2131–9.PubMedCrossRefGoogle Scholar
  11. 11.
    Stewart WF, Van Rooyen JB, Cundiff GW, et al. Prevalence and burden of overactive bladder in the United States. World J Urol. 2003;20:327.PubMedGoogle Scholar
  12. 12.
    Irwin DE, Milsom I, Hunskaar S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol. 2006;50:1306.PubMedCrossRefGoogle Scholar
  13. 13.
    Brøstrom S, Hallas J. Persistence of antimuscarinic drug use. Eur J Clin Pharmacol. 2009;65:309.PubMedCrossRefGoogle Scholar
  14. 14.
    Brubaker L, Richter HE, Visco A, Mahajan S, Nygaard I, Braun TM, Barber MD, Menefee S, Schaffer J, Weber AM, Wei J, Pelvic Floor Disorders Network. Refractory idiopathic urge urinary incontinence and botulinum A injection. J Urol. 2008;180(1):217–22.PubMedCrossRefPubMedCentralGoogle Scholar
  15. 15.
    Dmochowski R, Chapple C, Nitti VW, Chancellor M, Everaert K, Thompson C, Daniell G, Zhou J, Haag-Molkenteller C. Efficacy and safety of onabotulinumtoxinA for idiopathic overactive bladder: a double-blind, placebo controlled, randomized, dose ranging trial. J Urol. 2010;184(6):2416–22.PubMedCrossRefGoogle Scholar
  16. 16.
    Sahai A, Dowson C, Khan MS, Dasgupta P. Improvement in quality of life after botulinum toxin-A injections for idiopathic detrusor overactivity: results from a randomized double-blind placebo-controlled trial. BJU Int. 2009;103(11):1509–15.PubMedCrossRefGoogle Scholar
  17. 17.
    Visco AG, Brubaker L, Richter HE, Nygaard I, Paraiso MF, Menefee SA, Schaffer J, Lowder J, Khandwala S, Sirls L, Spino C, Nolen TL, Wallace D, Meikle SF, Pelvic Floor Disorders Network. Anticholinergic therapy vs. onabotulinumtoxinA for urgency urinary incontinence. N Engl J Med. 2012;367(19):1803–13.PubMedCrossRefPubMedCentralGoogle Scholar
  18. 18.
    Botox (botulinum toxin type A) package insert. Irvine, CA, Allergan Pharmaceuticals.Google Scholar
  19. 19.
    Shergill IS, Arya M, Hamid R, Khastgir J, Patel HR, Shah PJ. The importance of autonomic dysreflexia to the urologist. BJU Int. 2004;93(7):923–6.PubMedCrossRefGoogle Scholar
  20. 20.
    Nitti VW, Dmochowski R, Herschorn S, Sand P, Thompson C, Nardo C, Yan X, Haag-Molkenteller C, EMBARK Study Group. OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a Phase 3, randomized placebo controlled trial. J Urol. 2013;189(6):2186–93.PubMedCrossRefGoogle Scholar
  21. 21.
    Ingber MS, Vasavada SP, Moore CK, Rackley RR, Firoozi F, Goldman HB. Force of stream after sling therapy: safety and efficacy of rapid discharge care pathway based on subjective patient report. J Urol. 2011;185(3):993–7.PubMedCrossRefGoogle Scholar
  22. 22.
    Herschorn S, Gajewski J, Ethans K, Corcos J, Carlson K, Bailly G, Bard R, Valiquette L, Baverstock R, Carr L, Radomski S. Efficacy of botulinum toxin A injection for neurogenic detrusor overactivity and urinary incontinence: a randomized, double-blind trial. J Urol. 2011;185(6):2229–35.PubMedCrossRefGoogle Scholar
  23. 23.
    Wolf Jr JS, Bennett CJ, Dmochowski RR, Hollenbeck BK, Pearle MS, Schaeffer AJ, Urologic Surgery Antimicrobial Prophylaxis Best Practice Policy Panel. Best practice policy statement on urologic surgery antimicrobial prophylaxis. J Urol. 2008;179(4):1379–90.PubMedCrossRefGoogle Scholar
  24. 24.
    Wyndaele JJ, van Dromme SA. Muscular weakness as side effect of botulinum toxin injection for neurogenic detrusor overactivity. Spinal Cord. 2002;40:599–600.PubMedCrossRefGoogle Scholar
  25. 25.
    De Laet K, Wyndaele JJ. Adverse events after botulinum A toxin injection for neurogenic voiding disorders. Spinal Cord. 2005;43:397–9.PubMedCrossRefGoogle Scholar
  26. 26.
    Schulte-Baukloh H, Bigalke H, Heine G, et al. Antibodies against botulinum neurotoxin type A as a cause of treatment failure after the first detrusor injection. Urology. 2007;69(575):e13–5.PubMedGoogle Scholar
  27. 27.
    Kuo HC. Botulinum A toxin urethral injection for the treatment of lower urinary tract dysfunction. J Urol. 2003;170:1908–12.PubMedCrossRefGoogle Scholar
  28. 28.
    Dykstra DD, Sidi AA, Scott AB, Pagel JM, Goldish GD. Effects of botulinum A toxin on detrusor-sphincter dyssynergia in spinal cord injury patients. J Urol. 1988;139:919–22.PubMedGoogle Scholar
  29. 29.
    Schulte-Baukloh H, Weiss C, Stolze T, et al. Botulinum-A toxin detrusor and sphincter injection in treatment of overactive bladder syndrome: objective outcome and patient satisfaction. Eur Urol. 2005;48:984–90. discussion 990.PubMedCrossRefGoogle Scholar
  30. 30.
    Rogalski MJ, Kellogg-Spadt S, Hoffmann AR, Fariello JY, Whitmore KE. Retrospective chart review of vaginal diazepam suppository use in high-tone pelvic floor dysfunction. Int Urogynecol J. 2010;21(7):895–9.PubMedCrossRefGoogle Scholar
  31. 31.
    Abbott JA, Jarvis SK, Lyons SD, Thomson A, Vancaille TG. Botulinum toxin type A for chronic pain and pelvic floor spasm in women: a randomized controlled trial. Obstet Gynecol. 2006;108:915–23.PubMedCrossRefGoogle Scholar
  32. 32.
    Goldstein A. Intralevator injection of botulinum toxin for hypertonic pelvic floor. J Sex Med. 2011;8:1287–90.PubMedCrossRefGoogle Scholar
  33. 33.
    Smith CP, Radziszewski P, Borkowski A, Somogyi GT, Boone TB, Chancellor MB. Botulinum toxin a has antinociceptive effects in treating interstitial cystitis. Urology. 2004;64(5):871–5.PubMedCrossRefGoogle Scholar
  34. 34.
    Kuo HC. Repeated intravesical onabotulinumtoxinA injections are effective in treatment of refractory interstitial cystitis/bladder pain syndrome. Int J Clin Pract. 2013;67(5):427–34.PubMedCrossRefGoogle Scholar
  35. 35.
    Giannantoni A, Porena M, Costantini E, Zucchi A, Mearini L, Mearini E. Botulinum A toxin intravesical injection in patients with painful bladder syndrome: 1-year follow up. J Urol. 2008;179(3):1031–4.PubMedCrossRefGoogle Scholar
  36. 36.
    Pinto R, Lopes T, Frias B, Silva A, Silva JA, Silva CM, Cruz C, Cruz F, Dinis P. Trigonal injection of botulinum toxin A in patients with refractory bladder pain syndrome/interstitial cystitis. Eur Urol. 2010;58(3):360–5.PubMedCrossRefGoogle Scholar
  37. 37.
    Hanno PM, Burks DA, Clemens JQ, Dmochowski RR, Erickson D, Fitzgerald MP, Forrest JB, Gordon B, Gray M, Mayer RD, Newman D, Nyberg Jr L, Payne CK, Wesselmann U, Faraday MM, Interstitial Cystitis Guidelines Panel of the American Urological Association Education and Research, Inc. AUA guideline for the diagnosis and treatment of interstitial cystitis/bladder pain syndrome. J Urol. 2011;185(6):2162–70.PubMedCrossRefGoogle Scholar
  38. 38.
    Brown CS, Glazer HI, Vogt V, Menkes D, Bachmann G. Subjective and objective outcomes of botulinum toxin type A treatment in vestibulodynia: pilot data. J Reprod Med. 2006;51:635–41.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  1. 1.Saint Clare’s Health SystemDenvilleUSA
  2. 2.Weill Cornell Medical CollegeNew YorkUSA

Personalised recommendations